Hiroyuki Takamatsu

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 16

Top Topics

Peritoneal Dialysis

Multiple Myeloma

Anterior Cruciate Ligament Reconstruction

Top Venues

International journal of hematology

British journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Laurent Garderet, Luuk Gras, Linda Koster, Laurien Baaij, Nada Hamad, Anita Dsouza, Noel Estrada-Merly, Parameswaran Hari, Wael Saber, Andrew J Cowan, Minako Iida, Shinichiro Okamoto, Hiroyuki Takamatsu, Shohei Mizuno, Koji Kawamura, Yoshihisa Kodera, Bor Sheng Ko, Christopher Liam, Kim Wah Ho, A Sim Goh, S Keat Tan, Alaa M Elhaddad, Ali Bazarbachi, Qamar Un Nisa Chaudhry, Rozan Alfar, Mohamed-Amine Bekadja, Malek Benakli, Cristobal Augusto Frutos Ortiz, Eloísa Riva, Sebastian Galeano, Francisca Bass, Hira S Mian, Arleigh McCurdy, Feng Rong Wang, Meng Lv, Daniel Neumann, Mickey Koh, John A Snowden, Stefan Schönland, Donal P McLornan, Patrick John Hayden, Anna Sureda, Hildegard T Greinix, Mahmoud Aljurf, Yoshiko Atsuta, Dietger Niederwieser
Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT). American journal of hematology (2024)
Yasunori Kogure, Hiroshi Handa, Yuta Ito, Masaki Ri, Yuichi Horigome, Masaki Iino, Yoriko Harazaki, Takahiro Kobayashi, Masahiro Abe, Tadao Ishida, Shigeki Ito, Hiromi Iwasaki, Junya Kuroda, Hirohiko Shibayama, Kazutaka Sunami, Hiroyuki Takamatsu, Hideto Tamura, Toshiaki Hayashi, Kiwamu Akagi, Tomohiro Shinozaki, Takahiro Yoshida, Ikuo Mori, Shinsuke Iida, Takahiro Maeda, Keisuke Kataoka
ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone. Blood 143 (23) (2024)
Ryota Urushihara, Naoki Takezako, Takeshi Yoroidaka, Takeshi Yamashita, Ryoichi Murata, Kenji Satou, Shinji Nakao, Hiroyuki Takamatsu
Eight-color multiparameter flow cytometry (EuroFlow-NGF) is as sensitive as next-generation sequencing in detecting minimal/measurable residual disease in autografts of patients with multiple myeloma. EJHaem 4 (1) (2023)
Ryota Urushihara, Naoki Takezako, Takeshi Yoroidaka, Takeshi Yamashita, Ryoichi Murata, Kenji Satou, Shinji Nakao, Hiroyuki Takamatsu
Eight-color multiparameter flow cytometry (EuroFlow-NGF) is as sensitive as next-generation sequencing in detecting minimal/measurable residual disease in autografts of patients with multiple myeloma. EJHaem 4 (1) (2023)
Takamasa Katagiri, Jorge Luis Espinoza, Mizuho Uemori, Honoka Ikeda, Kohei Hosokawa, Ken Ishiyama, Takeshi Yoroidaka, Tatsuya Imi, Hiroyuki Takamatsu, Tatsuhiko Ozawa, Hiroyuki Kishi, Yasuhiko Yamamoto, Mahmoud Ibrahim Elbadry, Yoshinori Yoshida, Kazuhisa Chonabayashi, Katsuto Takenaka, Koichi Akashi, Yasuhito Nannya, Seishi Ogawa, Shinji Nakao
Hematopoietic stem progenitor cells with malignancy-related gene mutations in patients with acquired aplastic anemia are characterized by the increased expression of CXCR4. EJHaem 3 (3) (2022)
Daisuke Ikeda, Toshiki Terao, Ami Fukumoto, Yuka Uesugi, Rikako Tabata, Ayumi Kuzume, Takafumi Tsushima, Daisuke Miura, Kentaro Narita, Masami Takeuchi, Takeshi Yamashita, Hiroyuki Takamatsu, Matsue Kosei
Antibody status following booster vaccination against SARS-CoV-2 virus in patients with haematologic malignancies. British journal of haematology (2022)
Hiroyuki Takamatsu
Guest Editorial: Innovation will be a bridge to cure in patients with multiple myeloma? International journal of hematology 115 (6) (2022)
Hiroyuki Takamatsu, Takeshi Yoroidaka
Disappearance of bulky diffuse large B-cell lymphoma after methotrexate/infliximab withdrawal. International journal of hematology (2021)
Theodore E Liston, Aldric Hama, Johannes Boltze, Russell B Poe, Takahiro Natsume, Ikuo Hayashi, Hiroyuki Takamatsu, William S Korinek, James D Lechleiter
Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. Stroke (2021)
Paul Gerard Richardson, Aurore Perrot, Hiroyuki Takamatsu, null null
Revised international staging system allocation in the ICARIA-MM study: Practical challenges and impact on outcome. EJHaem 3 (1) (2021)
Takeshi Yamashita, Hiroyuki Takamatsu, Koji Kawamura, Kazutaka Sunami, Shotaro Hagiwara, Mitsuhiro Itagaki, Tsutomu Takahashi, Tadakazu Kondo, Takashi Ikeda, Kyoko Watakabe-Inamoto, Hiroshi Handa, Yoshitaka Imaizumi, Junya Kuroda, Jun Murakami, Yuichi Nakamura, Hideyuki Nakazawa, Shuji Ozaki, Miyuki Okura, Masami Takeuchi, Hirokazu Nagai, Ichiro Hanamura, Shinji Nakao, Shinsuke Iida
A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survival. British journal of haematology 195 (2) (2021)
Hiroyuki Takamatsu
Clinical value of measurable residual disease testing for multiple myeloma and implementation in Japan. International journal of hematology 111 (4) (2020)
Hiroyuki Takamatsu, Shinsuke Iida, Hirohiko Shibayama, Kazuhiro Shibayama, Hiroshi Yamazaki, Kenshi Suzuki
Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study. International journal of hematology 111 (5) (2020)
Hiroyuki Takamatsu, Takeshi Yoroidaka, Momoko Fujisawa, Kazuya Kobori, Masako Hanawa, Takeshi Yamashita, Ryoichi Murata, Mikio Ueda, Shinji Nakao, Kosei Matsue
Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry. International journal of hematology 109 (4) (2019)
Takashi Ikeda, Keita Mori, Koji Kawamura, Takehiko Mori, Shotaro Hagiwara, Yasunori Ueda, Kaoru Kahata, Naoyuki Uchida, Nobuhiro Tsukada, Satoshi Murakami, Masahide Yamamoto, Tsutomu Takahashi, Tatsuo Ichinohe, Makoto Onizuka, Yoshiko Atsuta, Yoshinobu Kanda, Shinichiro Okamoto, Kazutaka Sunami, Hiroyuki Takamatsu
Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation. Hematological oncology 37 (5) (2019)
Hiroyuki Takamatsu, Rachel K Wee, Yoshitaka Zaimoku, Ryoichi Murata, Jianbiao Zheng, Martin Moorhead, Victoria E H Carlton, Katherine A Kong, Naoki Takezako, Shigeki Ito, Toshihiro Miyamoto, Kenji Yokoyama, Matsue Kosei, Tsutomu Sato, Toshiro Kurokawa, Hideo Yagi, Yasushi Terasaki, Kinya Ohata, Morio Matsumoto, Takashi Yoshida, Malek Faham, Shinji Nakao
A comparison of minimal residual disease detection in autografts among ASO-qPCR, droplet digital PCR, and next-generation sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation. British journal of haematology 183 (4) (2017)